Phase III pivotal study of NKTR-214 plus Opdivo (nivolumab) in patients with melanoma and renal cell carcinoma.

Trial Profile

Phase III pivotal study of NKTR-214 plus Opdivo (nivolumab) in patients with melanoma and renal cell carcinoma.

Planning
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Nivolumab (Primary) ; NKTR 214 (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Mar 2018 New trial record
    • 01 Mar 2018 According to the Nektar Therapeutics media release, this study is to be initiated in mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top